Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia

Author(s):  Zur Eyal

Issue:  Mar/Apr 2019 - Volume 23, Number 2
View All Articles in Issue

Page(s):  113-119

Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 1
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 2
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 3
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 4
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 5
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 6
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Page 7

Download in electronic PDF format for $65

Abstract:  Schizophrenia is a serious, disabling, enduring, and relapsing mental illness which causes problems with the ability to think, feel, and perceive things clearly. One cause of relapse and readmission to a hospital is poor compliance with antipsychotic medication, often due to its adverse effects. Schizophrenia may also affect a person’s insight, interfering with their ability to appreciate the benefit of taking medication long term. The relapse rate is significantly higher in those who have discontinued antipsychotic medication. Penfluridol is an unusual, potent, long-acting, first-generation, oral antipsychotic agent indicated for the treatment of chronic schizophrenia, acute psychosis, and Tourette syndrome. It may be considered a depot medication, as it is administered once a week. Despite this positive analysis, and the unique added value of this medication to psychotic, non-compliant patients, Janssen-Cilag, the sole manufacturer of penfluridol worldwide, decided to stop production in 2009. This decision forced many psychotic patients worldwide to abandon the once-a-week convenient treatment and to replace it with a daily, oral treatment or a depot injection. Because penfluridol is no longer commercially available, it has created an opportunity for compounding pharmacists worldwide to accept this challenge and offer this medication to psychiatrists because of its clinical therapeutics. For the past 5 years, penfluridol has been available to compounding pharmacists in Israel and has received favorable feedback from physicians and patients.

Related Keywords: Eyal Zur, BSc Pharm, RPh, MBA, penfluridol, formulations, diphenylbutylpiperidine, chronic schizophrenia, antipsychotic agents, acute psychosis, Tourette syndrome, psychiatric disorders, postsynaptic dopamine receptor, mesolimbic dopaminergic system, neuroleptic adverse effects, drug interactions, herbal supplements, depot administration

Related Categories: FORMULATIONS, MENTAL HEALTH, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia
Zur Eyal
Mar/Apr 2019
Pg. 113-119

Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312

Burning Mouth Syndrome: A Discussion of a Complex Pathology
Zur Eyal
May/Jun 2012
Pg. 196-205

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report
Zur Eyal
Jan/Feb 2014
Pg. 14-19

Topical Treatment of Primary Focal Hyperhidrosis, Part 2
Zur Eyal
Mar/Apr 2019
Pg. 94-104

Haloperidol 0.5-mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Sep/Oct 2021
Pg. 417

Dopamine Hydrochloride 80-mg/mL Injection
Allen Loyd V Jr
Nov/Dec 2012
Pg. 505

Drug Therapy for Acute and Chronic Pain in the Cat
Lascelles B Duncan
Sep/Oct 2002
Pg. 338-343

Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents
Zur Eyal
Nov/Dec 2012
Pg. 462-469